2020
DOI: 10.35514/mtd.2020.29
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Treatment of Patients with SARS-CoV-2 in line with Literature

Abstract: The present article aimed to evaluate the drug therapy applied to patients who were followed up for SARS-CoV-2, and who were tested positive and negative 2019-nCov. Material and Methods:A comprehensive and systematic literature search of numerous electronic databases regarding patients SARS-CoV-2 was performed.Results: Patients with 2019-nCoV can be treated with ceftriaxone, moxifloxacin, oseltamivir, hydroxychloroquine, and patients with poor prognosis can also be given lopinavir/ritonavir. Conclusions: Not o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 29 publications
(39 reference statements)
0
2
0
Order By: Relevance
“…Pharmaceutical preparations such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, azithromycin, clarithromycin, moxifloxacin, acetylsalicylic acid, enoxaparin, dexamethasone, and paracetamol were used as mono or combined in the routine treatment of 2019-nCov cases examined in this review. Besides the aforementioned drugs, the use of atazanavir [17] or tocilizumab [5] have been reported in the literature.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Pharmaceutical preparations such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, azithromycin, clarithromycin, moxifloxacin, acetylsalicylic acid, enoxaparin, dexamethasone, and paracetamol were used as mono or combined in the routine treatment of 2019-nCov cases examined in this review. Besides the aforementioned drugs, the use of atazanavir [17] or tocilizumab [5] have been reported in the literature.…”
Section: Discussionmentioning
confidence: 99%
“…Studies on 2019-nCov [2][3][4] have reported typical clinical symptoms such as fever, cough, diarrhea, and fatigue. Furthermore, some anomalies have been reported in the characteristic laboratory and radiological examinations [5]. In some studies, it has been discovered that SARS-CoV-2 infection may cause damage to the central nervous system, especially the olfactory bulb, even when the infection is still in its early stages [6,7].…”
Section: Introductionmentioning
confidence: 99%